OMS 824
Alternative Names: OMS-643762; OMS-824Latest Information Update: 09 Aug 2019
At a glance
- Originator Nura
- Developer Omeros Corporation
- Class Antipsychotics
- Mechanism of Action Phosphodiesterase 10A inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Huntington's disease
- Suspended Schizophrenia
Most Recent Events
- 09 Aug 2019 OMS 824 is still in phase II trial for Huntington's disease in USA (PO) (Omeros Corporation pipeline, August 2019)
- 16 Mar 2017 Omeros Corporation has patent protection for OMS 824 in USA and ex-US countries
- 15 Mar 2016 Omeros plans to submit a phase II clinical trial protocol to the US FDA, for the treatment of Schizophrenia (Omeros, Form 10-K, March 2016)